

January 16, 2023

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto,
Chairman & CEO
(TSE Growth Code: 4593)

Announcement of Changes in Management

HEALIOS K.K. (“Healios”) announces the following changes in management at Healios and its subsidiary.

1. Changes of Executive Officers (January 1, 2023)

Healios newly established the position of CSO (Chief Scientific Officer) as the chief executive officer of the research department to promote research on eNK cells* and other programs in Japan and overseas. Healios changed its structure to achieve rapid R&D decision-making and rationalization of management in the field of regenerative medicine using somatic stem cells in light of the next development steps for ARDS (acute respiratory distress syndrome) and acute stroke becoming clear. Research and development in the field of iPSC regenerative medicines will be promoted under the leadership of the newly established CSO. Formerly Executive Officers, Mr. Nishiyama and Mr. Kotera will continue to serve the company as outside advisors to support the development and manufacturing operations as well as promotion of the business, and Mr. Abe will serve as the General Manager of the Human Resources & General Affairs Department.

Name	Current position	Former position
Masanori Sawada	Executive Vice President CMO (Chief Medical Officer) in charge of development & human resources and general affairs	Executive Vice President CMO (Chief Medical Officer)
Kouichi Tamura	Executive Officer CSO (Chief Scientific Officer) in charge of research and manufacturing Head of Kobe Research Institute	Executive Officer in charge of research Head of Kobe Research Institute

* Healios’ eNK cells are an iPSC-derived NK cell therapy with several functional enhancements achieved through gene-editing including enhanced recognition of and cytotoxicity towards cancer, improved persistence, increased capability to migrate to and infiltrate solid tumors, and the ability to recruit host immune cells.

Resignation as an Executive Officer (December 31, 2022)

Michihisa Nishiyama Executive Officer in charge of development
Koji Abe Executive Officer in charge of human resources and general affairs
Junichi Kotera Executive Officer in charge of manufacturing

2. Change of Directors and Executive Officers of subsidiaries, Healios NA, Inc.

In preparation for the full-scale research and development activities of eNK cells in North America, especially for the start of clinical trials in 2024, Mr. Tamura will become a non-executive director of Healios NA. Glenn Gormley and Paul Bresge, both outside directors of Healios, will be appointed as outside directors to support Helios' North American business and partner negotiation activities, drawing on their management experience in the North American pharmaceutical business and regenerative medicine field. Furthermore, in order to accelerate the North American business, Richard Kincaid, Healios' CFO and current President and CEO of Healios NA, will also serve as Chairman of Healios NA, and Mr. Kagimoto will concentrate on the management of Healios itself.

(January 1, 2023)

Name	Current position	Former position
Richard Kincaid	Chairman, President and CEO	President and CEO
Kouichi Tamura	Director	-

(December 12, 2022)

Name	Current position	Former position
Glenn Gormley	Director	-
Paul Bresge	Director	-

Resignation (December 31, 2022)

Hardy TS Kagimoto Chairman

Contact
IR & Finance and Accounting Division, HEALIOS K.K.
Mail: ir@healios.jp